At Astellas Oncology, we celebrate nurses for their courage.

Thank you to nurses everywhere for your bravery and strong voices as we work to change the course of cancer treatment together.

In 2024, it is estimated that there will be approximately 83,190 new cases of #BladderCancer in the U.S. This #BladderCancer AwarenessMonth and every month, we’re committed to supporting those impacted and raising awareness around #BladderCancer signs and symptoms.

As we reflect on #AML WorldAwarenessDay , we are inspired by the strength of those impacted by acute myeloid leukemia ( #AML ), from patients to caregivers. Learn more about AML, its impact, and the importance of genetic testing at know-aml.com.

From diagnosis, #GeographicAtrophy (GA) can spread to the center of the eye in just 2.5 years, potentially leading to blindness. That's why it's crucial to take charge of your eye health and protect your vision! Learn more about the symptoms GA: AskAboutGA.com

At Astellas, we recognize the impact acute myeloid leukemia ( #AML ) can have on patients and their caregivers. This #AML WorldAwarenessDay, we’re joining know AML to shine a light on the instrumental role caregivers play in supporting patients with AML. know-aml.com/understanding-….

Acute myeloid leukemia ( #AML ) can be caused by harmful mutations in genes which tell blood cells how to work, affecting more than 20,000 people in the U.S. in 2023.
This #AML WorldAwarenessDay, we encourage you to learn more and help raise awareness at know-aml.com/get-involved/w….

#GeographicAtrophy (GA) can start to develop with subtle symptoms, or even no symptoms at all. Regular eye exams are essential in detecting diseases like GA to stay ahead of vision loss.

Learn more about monitoring for GA: AskAboutGA.com

We look forward to connecting with leaders in optometry at the annual Vision Source Exchange Meeting in Orlando, Florida. Stop by booth #532 to hear why we are so passionate about the role of optometrists in the early detection and management of geographic atrophy.

Our team is eager to collaborate with retina specialists at the 12th Annual VBS - Vit Buckle Society Meeting. Hear more about our commitment to pioneering research for treatments in AMD and #GeographicAtrophy by stopping at booth #4.

We’re thrilled to be recognized on Fast Company's 2024 list of Most Innovative Companies in Medicine and Therapeutics! As a life science innovator, our focus is on developing pioneering medicines to help solve medical needs for patients: bit.ly/3x9KKdn

#FCMostInnovative

Our application has been accepted by China’s National Medical Products Administration for a combination therapy for advanced #UrothelialCancer , investigated with @Pfizer_news and Merck.

Read more: bit.ly/49gOrv9

We are excited to share that we have received a permanent J-Code (J2782) from the U.S. CMSGov for our treatment of #GeographicAtrophy . This milestone advances our efforts to ensure timely patient access to our treatment.

Read the full press release: bit.ly/49btKQU

Our anti-claudin 18.2 (CLDN18.2) antibody for the treatment of HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent #GastricCancer is now approved in Japan. Read more: bit.ly/3TRsA8Y

The European Medicines Agency’s #CHMP (Committee for Medicinal Products for Human Use) issued a positive opinion recommending marketing authorization of our #prostatecancer therapy, which may expand use to an add’l recurrent early form of the disease. bit.ly/3TsoSkS

Jim, who has been living with #ProstateCancer on and off for 15+ years, shares his story in the hope of inspiring and educating others navigating a prostate cancer diagnosis of their own: bit.ly/3UEWrlW

A #GastricCancer diagnosis can be devastating, and navigating all the information that comes with it can be an added burden. Our new YouTube channel, GI Cancer Chronicles, features real-life stories from those living with the disease: bit.ly/4c9Jc35

We’re excited to announce that following our December 2023 approval, the #FDA has granted #OrphanDrug and pediatric exclusivity to our #antifungal treatment for #InvasiveAspergillosis and #InvasiveMucormycosis in appropriate pediatric patients 1 to less than 18 years old.

Today, NEJM published our latest research in advanced #BladderCancer . This exciting new data is a testament to our commitment to bringing treatment options to patients with hard-to-treat #cancers . Learn more here: nejm.org/doi/full/10.10…

Introducing GI Cancer Chronicles, a new collection of #GastricCancer stories from patients, caregivers, and healthcare providers who navigate the disease daily. They’re sharing their real-life stories in the hopes of making the journey easier for others: bit.ly/4c9Jc35

#RareDiseaseDay is about generating change for those affected by #raredisease . Hear from our leaders about why they are passionate about working in rare diseases.